Atzumi (Dihydroergotamine) for Migraine

Overview
Atzumi is approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine attacks with or without aura in adults. It is not intended for the prevention of migraine attacks or for treating hemiplegic migraine headaches or migraine attacks with brainstem aura. Atzumi should only be used under the guidance of a healthcare provider, particularly for those with cardiovascular (heart-related) risk factors who may need evaluation prior to starting the medication. Atzumi is also known by its drug name, dihydroergotamine.

Atzumi belongs to a class of drugs called ergot alkaloids. It works by narrowing widened blood vessels in the brain, which is believed to relieve migraine symptoms.

How do I take it?
Prescribing information states that Atzumi is administered as a nasal powder using a special device. It’s delivered into a single nostril by squeezing the air pump three times. If needed, a second dose may be taken at least one hour later. The drug should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Atzumi include rhinitis (nasal inflammation), nausea, altered sense of taste, application site reactions, dizziness, vomiting, drowsiness, sore throat, and diarrhea.

Rare but serious side effects may include peripheral ischemia (restricted blood flow to the limbs), myocardial ischemia or infarction (reduced blood flow or heart attack), cerebrovascular events such as stroke or hemorrhage, hypertensive episodes (sudden high blood pressure), medication overuse headaches, preterm labor in pregnant individuals, and fibrotic complications (thickening of body tissues, including around the lungs or abdomen). Local nasal irritation may also occur and warrant discontinuation.

For more information about this treatment, visit:

Atzumi (Dihydroergotamine) Nasal Powder —  Satsuma Pharmaceuticals